On November 1, 2017 CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody therapeutics for the treatment of cancer, reported that it will present at the Jefferies 2017 London Healthcare Conference. Sean McCarthy, D.Phil., president and chief executive officer will deliver a corporate overview on November 15, 2017, at 4:40 p.m. BT (Press release, CytomX Therapeutics, NOV 1, 2017, View Source;p=RssLanding&cat=news&id=2313476 [SID1234521423]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Know more, wherever you are:
Latest on CytomX Therapeutics’ Cancer Pipeline, book your free 1stOncology demo here.

A live audio webcast of the presentation will be available through the Investors and News section of CytomX’s website. An archived replay will be available for 90 days following the event.